Nutraq acquired by Orkla
Context
Orkla completed its acquisition of NutraQ to strategically enhance its presence in high-growth market segments, specifically the health category and the direct-to-consumer (D2C) channel. The transaction provides Orkla with a new, subscription-based business model, diversifying its traditional go-to-market strategies and offering exciting growth opportunities. Orkla's leadership expressed admiration for the target's successful use of subscription solutions to build a significant customer base with direct home delivery. The strategic plan involves continuing the development of NutraQ's established concepts while simultaneously exploring new possibilities for applying the D2C model across Orkla's broader portfolio. To preserve the target's unique competencies and entrepreneurial culture, NutraQ will continue to operate as a stand-alone entity within the Orkla Care business area, with its existing executive management team remaining in place. The deal represents a logical next step for NutraQ, transitioning it from private equity ownership under Impilo and Sana Pharma Holding to a long-term industrial owner poised to support its next phase of growth and expansion. The transaction received all necessary approvals from relevant competition authorities prior to its completion.
Nutraq, which reported an EBITDA margin of [members only] in 2020, is valued in this transaction at an EV/EBITDA multiple of 15x–25x.
-> Deep-dive in Healthcare & Pharma market trends
Target
NutraQ is a prominent supplier specializing in subscription-based health and wellness products, primarily serving the Nordic market. Established in Norway in 2002, the company has since expanded its operational footprint to include Denmark, Finland, Sweden, the Czech Republic, Slovakia, the Netherlands, and Poland. Despite this expansion, the four Nordic countries consistently constitute the vast majority of its turnover. The company's core business model is centered on a direct-to-consumer (D2C) approach, leveraging subscription services to deliver a range of health and wellness concepts directly to customers' homes. This model has proven successful, supporting significant organic growth in its customer base; in the period 2018-2020, the number of active subscriptions grew by an average of 13 percent per year. Headquartered in Oslo, Norway, NutraQ operates with a dedicated team of approximately 170 employees. The company's strategy focuses on building and maintaining strong customer relationships through its recurring revenue model and continuously developing attractive product offerings within the health and wellness space. Its well-established platform is designed to support further growth and geographic expansion.
Ent. Value
NOK 1–10bn
Equity Value
[members only]
Multiples
EV / Revenue
2x–6x
EV / EBITDA
15x–25x
EV / EBIT
[members only]
Historical Financials (NOK)
Other operations with Orkla
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 07/2026 | ORKLA | THE EUROPEAN CANDY GROUP | NETHERLANDS | Food Products |
| 05/2026 | ORKLA | PHOENIX BRANDS | UNITED KINGDOM | Food Products |
| 10/2022 | ORKLA | DENALI INGREDIENTS | UNITED STATES | Ingredients |
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 11/2021 | ESSLING CAPITAL / MULTICROISSANCE / BOURRELIER GROUP | TEKNIMED | FRANCE | Implants & Prosthetics |
| 09/2021 | PERRIGO COMPANY | HRA PHARMA | FRANCE | Generics / Labs |
| 07/2021 | MONTAGU PRIVATE EQUITY | INTECH MEDICAL | FRANCE | Implants & Prosthetics |
| 07/2021 | PARTNERS GROUP | PHARMATHEN | GREECE | CDMO |
| 04/2021 | NESTLE | THE BOUNTIFUL COMPANY | UNITED STATES | Nutrition & Dietary Supplements |
| 04/2021 | NAXICAP PARTNERS | LAGARRIGUE | FRANCE | Implants & Prosthetics |
| 04/2021 | DIASORIN | LUMINEX CORPORATION | UNITED STATES | Diagnostic Equipment |
| 03/2021 | CVC | COOPER-VEMEDIA | FRANCE | Generics / Labs |
| 02/2021 | IK PARTNERS | INNOVAD GROUP | BELGIUM | Animal Health |
| 02/2021 | SIPAREX | WINNCARE | FRANCE | Medical Devices |
REFERENCES
Valuation range: EV NOK 1–10bn
Revenue range: NOK 450–900M
EBITDA range: NOK 100–200M
EV/Revenue range: 2x - 6x
EV/EBITDA range: 15x - 25x
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Nutraq by Orkla are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Target: nutraq
FAQ
What transaction does this page cover?
How was the acquisition of Nutraq by Orkla valued, and what multiples were paid?
What were Nutraq’s revenue and EBITDA at the time of the deal?
What sources support the information on this transaction?
What is mynth?